Venture-backed Zymeworks closes buy of Kairos Therapeutics
Zymeworks Inc has closed its previously announced acquisition of Kairos Therapeutics Inc, a specialist in antibody drug conjugates. No financial terms were disclosed. The merger of the two Vancouver-based companies creates "one of the industry's leading biologics drug discovery and development organizations," Zymeworks said. Zymeworks, a developer of antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases, secured about $87 million (US$61.5 million) in a Series A financing in January. The round was co-led by BDC Capital and Lumira Capital.
24 March 2016•4 mins read
